GCGR Agonist

GLP-1 receptor agonist 17-d₃ (Compound 701) is the deuterium labeled GLP-1R agonist 17 (HY-148212). GLP-1R agonist 17 is a GLP-1 receptor agonist that can be used for the research of cardiovascular metabolic diseases.

TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC₅₀ values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes.

Exendin 4, biotin labeled is a biotin labeled Exendin 4 (HY-13443). Exendin 4 is a long-acting GLP-1 receptor agonist.

GCGR/GLP‐1 receptor agonist P1 is a dual GCGR/GLP-1R agonist. GCGR/GLP‐1 receptor agonist P1 activates human GCGR in vitro and induces the cyclic adenosine monophosphate (cAMP) signaling pathway. GCGR/GLP‐1 receptor agonist P1 is applicable to research related to type 2 diabetes and obesity.

(Asp28)-Glucagon (1-29) (human, rat, porcine) is a glucagon analog and a GCGR agonist, with the Asn at position 28 replaced by Asp. (Asp28)-Glucagon (1-29) (human, rat, porcine) activates GCGR-mediated cAMP signaling, with EC₅₀ values of 0.067 nM and 0.09 nM, respectively, and an EC₅₀ of 7.99 nM for GLP-1R. (Asp28)-Glucagon (1-29) (human, rat, porcine) is useful for studies on glucagon receptor signaling, carbohydrate metabolism, and hypoglycemia.

OXM-7 is a dual agonist of GLP-1R (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism.

A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function.

GLP-1R agonist 32 (Compound 111) is an orally active and highly potent GLP-1R agonist with an EC₅₀ value of 0.017 nM. GLP-1R agonist 32 exerts glucose-regulating activity by activating GLP-1R to stimulate cAMP production, promoting insulin secretion, inhibiting glucagon release, and delaying gastric emptying. GLP-1R agonist 32 is promising for research of type 2 diabetes, obesity, and related metabolic disorders.

TPM003 (TG062) is a triple agonist of GLP-1R, GIPR and GCGR, with EC₅₀ values of 33.9, 12.5 and 92.9 pM, respectively. TPM003 suppresses appetite, regulates blood glucose, enhances insulin sensitivity, reduces gastrointestinal intolerance, promotes hepatic lipid mobilization and increases energy expenditure. TPM003 induces weight loss, improves metabolic parameters, reverses hepatic steatosis and optimizes liver function markers. TPM003 is applicable for research on obesity and non-alcoholic steatohepatitis.

Retatrutide, Pro40(¹³C₅,¹⁵N) (LY3437943, Pro40(¹³C₅,¹⁵N) TFA) is the ¹³C, ¹⁵N-labeled Retatrutide (HY-P3506). Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.

Shanzhiside methyl ester (Standard) is the analytical standard of Shanzhiside methyl ester. This product is intended for research and analytical applications. Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance.

BETP (Standard) is the analytical standard of BETP (HY-103546). This product is intended for research and analytical applications. BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC₅₀s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.

Orforglipron (Standard) is the analytical standard of Orforglipron (HY-112185). This product is intended for research and analytical applications. Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete.

Danuglipron (PF-06882961) tromethamine is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron tromethamine has the potential for type 2 diabetes research.